Images of the K-Clip annuloplasty system by Shanghai Huihe Medical Technology Co. Images courtesy of the International Journal of Cardiology andZhang et al.
Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary.
Images taken from the SCCT's expert consensus document on using CT to treat congenital heart disease: A bioprosthetic valve visualized in a normally positioned RVOT (A) and in the dilated neo-RVOT after LeCompte maneuver (B). Images courtesy of SCCT and Han et al.
The group collaborated with two other medical societies, SCAI and CHSS, on the expert consensus document.
Images of the VDyne transcatheter tricuspid valve replacement (TTVR) prosthesis courtesy of EuroIntervention andSorajja et al. View the study for detailed captions.
Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.
Cathleen Dalton Biga, MSN, RN, and Christopher Kramer, MD
ACC Vice President Cathleen Dalton Biga, MSN, RN, will serve as the group's next president. Cardiologist Christopher Kramer, MD, will be its next vice president.
Abbott's TriClip device for TEER in patients with tricuspid regurgitation.
The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.
